208 related articles for article (PubMed ID: 16028169)
1. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.
Pérez-Trallero E; Marimón JM; González A; Ercibengoa M; Larruskain J
Clin Infect Dis; 2005 Aug; 41(4):560-4. PubMed ID: 16028169
[TBL] [Abstract][Full Text] [Related]
2. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
[TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Iraurgui P; Torres MJ; Aznar J
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.
Desai H; Richter S; Doern G; Heilmann K; Dohrn C; Johnson A; Brauer A; Murphy T; Sethi S
COPD; 2010 Oct; 7(5):337-44. PubMed ID: 20854048
[TBL] [Abstract][Full Text] [Related]
5. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
[TBL] [Abstract][Full Text] [Related]
6. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
[TBL] [Abstract][Full Text] [Related]
7. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
Schurek KN; Adam HJ; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294
[TBL] [Abstract][Full Text] [Related]
8. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Fuller JD; Low DE
Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone-resistant Streptococcus pneumoniae.
Pletz MW; Fugit RV; McGee L; Glasheen JJ; Keller DL; Welte T; Klugman KP
Emerg Infect Dis; 2006 Sep; 12(9):1462-3. PubMed ID: 17073107
[No Abstract] [Full Text] [Related]
10. Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.
Smith-Adam HJ; Nichol KA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2005 Feb; 49(2):846-8. PubMed ID: 15673786
[TBL] [Abstract][Full Text] [Related]
11. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
Low DE
Clin Infect Dis; 2004 May; 38 Suppl 4():S357-62. PubMed ID: 15127370
[TBL] [Abstract][Full Text] [Related]
12. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
Bhavnani SM; Hammel JP; Jones RN; Ambrose PG
Diagn Microbiol Infect Dis; 2005 Jan; 51(1):31-7. PubMed ID: 15629226
[TBL] [Abstract][Full Text] [Related]
13. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
[TBL] [Abstract][Full Text] [Related]
14. Emergence of rifampin-resistant Streptococcus pneumoniae as a result of antimicrobial therapy for penicillin-resistant strains.
van Tilburg PM; Bogaert D; Sluijter M; Jansz AR; de Groot R; Hermans PW
Clin Infect Dis; 2001 Oct; 33(8):e93-6. PubMed ID: 11550121
[TBL] [Abstract][Full Text] [Related]
15. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.
Pletz MW; McGee L; Beall B; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2005 Feb; 49(2):779-80. PubMed ID: 15673766
[TBL] [Abstract][Full Text] [Related]
16. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.
Davies TA; Yee YC; Goldschmidt R; Sahm DF; Evangelista AT
Postgrad Med; 2008 Sep; 120(3 Suppl 1):39-45. PubMed ID: 18931470
[TBL] [Abstract][Full Text] [Related]
17. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
[TBL] [Abstract][Full Text] [Related]
19. The relationship between serotypes and PFGE genotypes in isolates of Streptococcus pneumoniae from Hungary.
Dobay O; Rozgonyi F; Hajdú E; Nagy E; Knausz M; Amyes SG
Clin Microbiol Infect; 2005 Aug; 11(8):673-6. PubMed ID: 16008622
[TBL] [Abstract][Full Text] [Related]
20. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.
Morrissey I; Colclough A; Northwood J
Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
